You are here

  • Home
  • Archive
  • Volume 31, Issue 10
  • Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Citation Tools

Article menu
Download PDFPDF
Clinical trial
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Musacchio L, Salutari V, Pignata S, et al
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
International Journal of Gynecologic Cancer 2021;31:1369-1373.